Sapience Therapeutics

Sapience Therapeutics is a clinical-stage biotechnology company focused on eliminating hard-to-treat cancers. It describes its SPEARs™ as acting inside cancer cells and its SPARCs™ as acting on the outside, and states that two SPEARs, lucicebtide (formerly ST101) and ST316, are in Phase 2 trials. The company also describes its ADAPT™ and PADS™ peptide discovery and development platforms. Barry Kappel is the founder, President, Chief Executive Officer and Director.

Sapience Therapeutics is a clinical-stage biotechnology company focused on eliminating hard-to-treat cancers. It states that it has advanced peptide therapeutics by bringing together experts across peptide chemistry, molecular biology, immunology and oncologic drug development. The company describes its SPEARs™ as acting inside cancer cells and its SPARCs™ as acting on the outside, and states that two SPEARs, lucicebtide (formerly known as ST101) and ST316, are in Phase 2 trials. It also describes its ADAPT™ and PADS™ platforms as purpose-built to maximize the translational potential of drug candidates. Barry Kappel is the founder, President, Chief Executive Officer and Director of Sapience Therapeutics.

Clinical-stage biotechnology company bringing expertise and innovation to eliminating hard-to-treat cancers through peptide therapeutics.

• Lucicebtide (ST101)

• ST316

• 2020.12.01

  Reported2020.12.01

  Sapience Therapeutics appoints J. Andrew Sanford to its board[5]Sapience Therapeutics任命J. Andrew Sanford为董事会成员finanznachrichten.de

  Sapience Therapeutics announced that it appointed J. Andrew Sanford to its board of directors.

Read more

1. 1Home - Sapience Therapeuticssapiencetherapeutics.com
2. 2About Us - Sapience Therapeuticssapiencetherapeutics.com
3. 3Management Team - Sapience Therapeuticssapiencetherapeutics.com
4. 4Advisors - Sapience Therapeuticssapiencetherapeutics.com
5. 5Sapience Therapeutics任命J. Andrew Sanford为董事会成员finanznachrichten.de